Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
The prevention and management of chronic kidney disease among patients with metabolic syndrome.
Zhu D. et al, (2025), Kidney Int
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.
Zhu D. et al, (2025), Nephrol Dial Transplant, 40, i70 - i79
In adults with BMI ≥27 kg/m2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA1c level.
Zhu D. and Herrington WG., (2024), Ann Intern Med, 177
In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.
Zhu D. and Herrington WG., (2024), Ann Intern Med, 177
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Improvements in Kidney Outcomes Over the Years: Reason for Optimism but a Challenge for Trialists.
Zhu D. et al, (2024), Am J Kidney Dis, 83, 427 - 428
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 51 - 60